Document Detail


Clinical pharmacology of portal hypertension.
MedLine Citation:
PMID:  20951924     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Portal hypertension is an increase in pressure in the portal vein and its tributaries. It is defined as a portal pressure gradient (the difference in pressure between the portal vein and the hepatic veins) greater than 5 mm Hg. Although this gradient defines portal hypertension, a gradient of 10 mm Hg or greater defines clinically significant portal hypertension, because this pressure gradient predicts the development of varices, decompensation of cirrhosis, and hepatocellular carcinoma. The most direct consequence of portal hypertension is the development of gastroesophageal varices that may rupture and lead to the development of variceal hemorrhage. This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage.
Authors:
Cecilia Miñano; Guadalupe Garcia-Tsao
Related Documents :
8440794 - Comparison of the hemodynamic effects of hydroxocobalamin and cobalt edetate at equipot...
1129264 - Vasoactive intestinal polypoptide: inactivation in liver and potentiation in lung of an...
8435014 - Exclusion criteria and outcome in pressure reduction of intussusception.
20630674 - Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology.
8538824 - Diagnosis and therapeutic aspects of stroke.
12142194 - Hemodynamics optimization during off-pump coronary artery bypass: the 'no compression' ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gastroenterology clinics of North America     Volume:  39     ISSN:  1558-1942     ISO Abbreviation:  Gastroenterol. Clin. North Am.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-18     Completed Date:  2011-02-04     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  8706257     Medline TA:  Gastroenterol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  681-95     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use
Fibrosis / complications
Hemorrhage / drug therapy,  prevention & control,  surgery
Humans
Hypertension, Portal / drug therapy*,  etiology,  physiopathology*
Liver / blood supply
Randomized Controlled Trials as Topic
Somatostatin / administration & dosage,  analogs & derivatives,  therapeutic use
Varicose Veins / physiopathology,  prevention & control
Vasoconstrictor Agents / therapeutic use
Vasodilator Agents / therapeutic use
Vasopressins / administration & dosage,  therapeutic use
Grant Support
ID/Acronym/Agency:
K24 DK002727/DK/NIDDK NIH HHS; K24 DK002727-10/DK/NIDDK NIH HHS; P30 DK034989/DK/NIDDK NIH HHS; P30 DK034989-277468/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Vasoconstrictor Agents; 0/Vasodilator Agents; 11000-17-2/Vasopressins; 51110-01-1/Somatostatin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New pharmacologic therapies in chronic hepatitis B.
Next Document:  Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and col...